PCI术后标准双联抗血小板治疗不耐受的处理策略

王云云; 乌云其达木改; 周强

doi:10.13201/j.issn.1001-1439.2021.05.004

PCI术后标准双联抗血小板治疗不耐受的处理策略

- 华中科技大学同济医学院附属同济医院心血管内科(武汉,430030)

详细信息

通讯作者: 周强,E-mail:thisiszhou@163.com

中图分类号: R541.4

收稿日期: 2020-09-21

修回日期: 2020-12-01

Strategies for intolerance of standard dual antiplatelet therapy after PCI

- Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

More Information

Corresponding author: ZHOU Qiang, E-mail: thisiszhou@163.com

Received Date: 21 September 2020

Revised Date: 01 December 2020

摘要

摘要: 双联抗血小板治疗(DAPT)是目前冠心病患者行经皮冠状动脉介入治疗(PCI)术后的基础治疗,是减少包括支架内血栓形成在内的心血管缺血事件的关键。阿司匹林和一种P2Y12受体抑制剂联用在稳定性冠心病(SACD)患者PCI术后维持6个月,急性冠状动脉综合征(ACS)维持12个月是目前的标准DAPT策略,但在临床实践过程中,部分患者因出现胃肠道不适、出血、呼吸困难等不良反应不能耐受标准DAPT,导致自行停药,增加心血管不良事件发生风险。现结合临床实践及证据对PCI术后标准DAPT不耐受的处理策略进行综述。
- 经皮冠状动脉介入治疗 /
- 双联抗血小板治疗 /
- 阿司匹林 /
- P2Y12受体抑制剂
Abstract: Dual antiplatelet therapy(DAPT)is the basic therapy for patients with coronary artery disease undergoing percutaneous coronary intervention(PCI),which is the key to reducing cardiovascular ischemic events including stent thrombosis. DAPT is the standard of care consisting of aspirin and a P2 Y12 receptor inhibitor for 6 months in stable coronary artery disease(SCAD) and 12 months in acute coronary syndromes(ACS). However, in the clinical practice, some patients cannot tolerate standard DAPT because of gastrointestinal discomfort, bleeding, dyspnea and other adverse reactions, which leads to self-discontinuation of the drug and increasing the risk of cardiovascular adverse events. This article will review the strategies for intolerance of standard DAPT after PCI based on clinical practice and evidence.
- percutaneous coronary intervention /
- dual antiplatelet therapy /
- aspirin /
- P2Y12 receptor inhibitor

HTML全文

参考文献(36)

[1]	Leon MB,Baim DS,Popma JJ,et al.A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting.Stent Anticoagulation Restenosis Study Investigators[J].N Engl J Med,1998,339(23):1665-1671.
[2]	Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology( ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)[J].Eur Heart J,2018,39(3):213-260.
[3]	Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J].Eur Heart J,2019,40(2):87-165.
[4]	Tournoij E,Peters RJ,Langenberg M,et al.The prevalence of intolerance for low-dose acetylsalicylacid in the secondary prevention of atherothrombosis[J].Eur J Vasc Endovasc Surg,2009,37(5):597-603.
[5]	Nakamura M,Kimura K,Kimura T,et al.JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease[J].Circ J,2020,84(5):831-865.
[6]	Watanabe H,Domei T,Morimoto T,et al.Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI:The STOPDAPT-2 Randomized Clinical Trial[J].JAMA,2019,321(24):2414-2427.
[7]	Hahn JY,Song YB,Oh JH,et al.Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention:The SMART-CHOICE Randomized Clinical Trial[J].JAMA,2019,321(24):2428-2437.
[8]	Vranckx P,Valgimigli M,Jüni P,et al.Ticagrelor plus aspirin for 1 month,followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months,followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent:a multicentre,open-label,randomised superiority trial[J].Lancet,2018,392(10151):940-949.
[9]	Mehran R,Baber U,Sharma SK,et al.Ticagrelor with or without Aspirin in High-Risk Patients after PCI[J].N Engl J Med,2019,381(21):2032-2042.
[10]	Chen PW,Feng WH,Ho MY,et al.P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[J].J Clin Med,2020,9(6).
[11]	de Donato G,Setacci F,Mele M,et al.Restenosis after Coronary and Peripheral Intervention:Efficacy and Clinical Impact of Cilostazol[J].Ann Vasc Surg,2017,41:300-307.
[12]	Xue Y,Feng ZW,Li XY,et al.The efficacy and safety of cilostazol as an alternative to aspirin in Chinese patients with aspirin intolerance after coronary stent implantation:a combined clinical study and computational system pharmacology analysis[J].Acta Pharmacol Sin,2018,39(2):205-212.
[13]	Dai C,Chen Z,Fu J,et al.Cilostazol for Chinese Patients with Aspirin Intolerance after Coronary Drug-Eluting Stent Implantation[J].Thromb Haemost,2020,120(5):857-865.
[14]	Lee JY,Sung KC,Choi HI.Comparison of aspirin and indobufen in healthy volunteers[J].Platelets,2016,27(2):105-109.
[15]	罗东雷,郭靖涛,王文静.冠心病患者服用阿司匹林致胃炎伴糜烂加重换用吲哚布芬1例[J].中国循证心血管医学杂志,2019,11(6):752-753.
[16]	刘怡,姜红菊.吲哚布芬与阿司匹林治疗急性冠脉综合征的疗效比较[J].实用医药杂志,2020,37(7):616-618.
[17]	Kubisa MJ,Jezewski MP,Gasecka A,et al.Ticagrelor-toward more efficient platelet inhibition and beyond[J].Ther Clin Risk Manag,2018,14:129-140.
[18]	Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
[19]	Goto S,Huang CH,Park SJ,et al.Ticagrelor vs.clopidogrel in Japanese,Korean and Taiwanese patients with acute coronary syndrome--randomized,double-blind,phase III PHILO study[J].Circ J,2015,79(11):2452-2460.
[20]	Levine GN,Jeong YH,Goto S,et al.Expert consensus document:World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI[J].Nat Rev Cardiol,2014,11(10):597-606.
[21]	Krakowiak A,Kuleta J,Plech I,et al.Ticagrelor-Related Severe Dyspnoea:Mechanisms,Characteristic Features,Differential Diagnosis and Treatment[J].Clin Med Insights Case Rep,2020,13:1179547620956634.
[22]	Arora S,Shemisa K,Vaduganathan M,et al.Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD:JACC Review Topic of the Week[J].J Am Coll Cardiol,2019,73(19):2454-2464.
[23]	Schiele F,Puymirat E,Bonello L,et al.Switching between thienopyridines in patients with acute myocardial infarction and quality of care[J].Open Heart,2016,3(1):e000384.
[24]	Angiolillo DJ,Patti G,Chan KT,et al.De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients:a systematic review and meta-analysis[J].J Thromb Thrombolysis,2019,48(1):1-10.
[25]	Cuisset T,Deharo P,Quilici J,et al.Benefit of switching dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study[J].Eur Heart J,2017,38(41):3070-3078.
[26]	Sibbing D,Aradi D,Jacobshagen C,et al.Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention(TROPICAL-ACS):a randomised,open-label,multicentre trial[J].Lancet,2017,390(10104):1747-1757.
[27]	Motovska Z,Hlinomaz O,Kala P,et al.1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor[J].J Am Coll Cardiol,2018,71(4):371-381.
[28]	Bonaca MP,Bhatt DL,Cohen M,et al.Long-term use of ticagrelor in patients with prior myocardial infarction[J].N Engl J Med,2015,372(19):1791-800.
[29]	Kubica J,Adamski P,Buszko K,et al.Platelet inhibition with standard vs.lower maintenance dose of ticagrelor early after myocardial infarction(ELECTRA):a randomized,open-label,active-controlled pharmacodynamic and pharmacokinetic study[J].Eur Heart J Cardiovasc Pharmacother,2019,5(3):139-148.
[30]	Yeh RW,Kereiakes DJ,Steg PG,et al.Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction[J].J Am Coll Cardiol,2015,65(20):2211-2221.
[31]	Piccolo R,Bonaa KH,Efthimiou O,et al.Drug-eluting or bare-metal stents for percutaneous coronary intervention:a systematic review and individual patient data meta-analysis of randomised clinical trials[J].Lancet,2019,393(10190):2503-2510.
[32]	Moon JY,Franchi F,Rollini F,et al.Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy[J].Prog Cardiovasc Dis,2018,60(4-5):478-490.
[33]	Schulz-Schüpke S,Byrne RA,Ten Berg JM,et al.ISAR-SAFE:a randomized,double-blind,placebo-controlled trial of 6 vs.12 months of clopidogrel therapy after drug-eluting stenting[J].Eur Heart J,2015,36(20):1252-1263.
[34]	Costa F,van Klaveren D,James S,et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy(PRECISE-DAPT)score:a pooled analysis of individual-patient datasets from clinical trials[J].Lancet,2017,389(10073):1025-1034.
[35]	Benenati S,Galli M,De Marzo V,et al.Very short vs.long dual antiplatelet therapy after second generation drug-eluting stents in 35,785 patients undergoing percutaneous coronary interventions:a Meta-analysis of Randomised Controlled Trials[J].Eur Heart J Cardiovasc Pharmacother,2020.
[36]	Yeh RW,Secemsky EA,Kereiakes DJ,et al.Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention[J].JAMA,2016,315(16):1735-1749.